Biological
FBX-101
FBX-101 is a biological therapy with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)
Phase Distribution
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Active, not recruiting2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
active_not_recruiting267%
terminated133%
Recent Activity
2 active trials
Showing 3 of 3
active_not_recruitingphase_1
Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT
NCT05739643
terminated
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
NCT06308718
active_not_recruitingphase_1
Gene Transfer Clinical Trial for Krabbe Disease
NCT04693598
Clinical Trials (3)
Showing 3 of 3 trials
NCT05739643Phase 1
Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT
NCT06308718
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
NCT04693598Phase 1
Gene Transfer Clinical Trial for Krabbe Disease
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3